On December 5, 2016 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported that clinical data for lirilumab and IPH4102 were presented in two posters at the American Society of Hematology (ASH) (Free ASH Whitepaper)’s (ASH) (Free ASH Whitepaper) 2016 Annual Meeting (December 3-6, 2016), San Diego, CA, U.S.:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster 1826 entitled "First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results" was presented by Prof. Y. Kim from the Stanford Cancer Institute and investigator of the study(Press release, Innate Pharma, DEC 4, 2016, View Source [SID1234516908]). IPH4102 is Innate Pharma’s wholly-owned first-in-class anti-KIR3DL2 antibody.
This poster presented preliminary results from the first seven dose levels of the dose-escalation part of the Phase I trial of IPH4102 (1). They showed that the drug candidate is well tolerated in patients with relapsed/refractory CTCL (2) and a preliminary global objective response rate (ORR) of 38% in the evaluable population across all dosage levels.

Explorative assessments show that clinical improvement in skin comes along with decreases of malignant cells and normalization of immune parameters in the tumor microenvironment. All responses were ongoing at the time of poster presentation.

Dose level 8 (3 mg/kg) has been completed without dose-limiting toxicity. Two further dose levels (6 and 10 mg/kg) remain to be explored in the dose-escalation part of this study.

Poster 1641 entitled "Phase IB/II Study of Lirilumab in Combination with Azacytidine in Patients with Relapsed Acute Myeloid Leukemia" was presented by Dr N. Daver from the Department of Leukemia at the MD Anderson Cancer Center.
Lirilumab is a first-in-class fully human monoclonal antibody that blocks inhibitory killer-cell immunoglobulin-like receptors (KIRs) expressed predominantly on natural killer (NK) cells to potentiate an anti-tumor immune response mediated by the latter. Lirilumab is licensed to Bristol-Myers Squibb Company by Innate Pharma.

In this Phase Ib/II study testing lirilumab in combination with azacytidine in a heavily pretreated patient population with relapsed AML, full doses of azacytidine and lirilumab (3) were well tolerated. No dose-limiting toxicities were observed. Preliminary efficacy data for 25 evaluable patients showed a response rate of 20% including two patients achieved a CR (4) or a CR with insufficient count recovery and three achieving hematologic improvement.

"Preliminary results presented at ASH (Free ASH Whitepaper) 2016 are encouraging, as they further reinforce the favorable safety profile of both lirilumab and IPH4102. The study of IPH4102 conducted in patients with CTCL is progressing very well and we look forward to the completion of the dose-escalation part of the trial to confirm the encouraging efficacy signal seen across dose levels to date," said Pierre Dodion, Chief Medical Officer of Innate Pharma. "The good safety profile of lirilumab in combination with azacytidine in patients with relapsed AML further supports the view that lirilumab is well tolerated in numerous combinations."

Posters Details

IPH4102

Poster title: "First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results"
Date: Saturday, December 3, 2016
Time: 5:30 p.m. – 7:30 p.m. PST
Presenter: Pr Youn Kim, Division of Oncology, Department of Medicine, Stanford Cancer Institute, Palo Alto, CA, U.S
Location: Hall GH, San Diego Convention Center, San Diego, CA, U.S.
The poster #1826 is available on Innate Pharma’s website.

Lirilumab

Poster title: "Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)"
Date: Saturday, December 3, 2016
Time: 5:30 p.m. – 7:30 p.m. PST
Presenter: Dr Naval Daver, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.
Location: Hall GH, San Diego Convention Center, San Diego, CA, U.S.
The poster #1641 will be soon available on Innate Pharma’s website.